Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
BackgroundWhile neoadjuvant chemoimmunotherapy shows promise for locally advanced esophageal squamous cell carcinoma (ESCC), optimal regimen selection remains challenging. This study compares perioperative outcomes between camrelizumab- and tislelizumab-based neoadjuvant chemoimmunotherapy in ESCC.M...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544739/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849232662440443904 |
|---|---|
| author | Qi Zhao Yusen Yuan Tongxin Xu Ningning Yan Fei Li Juntao Lu Ming He Zhaoyang Yan |
| author_facet | Qi Zhao Yusen Yuan Tongxin Xu Ningning Yan Fei Li Juntao Lu Ming He Zhaoyang Yan |
| author_sort | Qi Zhao |
| collection | DOAJ |
| description | BackgroundWhile neoadjuvant chemoimmunotherapy shows promise for locally advanced esophageal squamous cell carcinoma (ESCC), optimal regimen selection remains challenging. This study compares perioperative outcomes between camrelizumab- and tislelizumab-based neoadjuvant chemoimmunotherapy in ESCC.MethodsWe conducted a retrospective analysis of 209 clinical stage II-IVA ESCC patients treated at Hebei Medical University Fourth Hospital (October 2020-December 2023) who underwent neoadjuvant chemoimmunotherapy (camrelizumab, n=119; tislelizumab, n=90) followed by esophagectomy.ResultsComparable pathological responses were observed between groups: pathological complete response (31.1% vs 30.3%, P=1.00), major pathological response (44.4% vs 42.9%, P=0.89), and pathological downstaging (67.8% vs 73.9%, P=0.36). Perioperative complication rates, including hematologic toxicities, immune-related adverse events, and surgical complications, were similar (all P>0.05). The tislelizumab group demonstrated significantly lower unplanned ICU transfer rates (P=0.04), while operative parameters (duration, blood loss, R0 resection) showed no differences.ConclusionTislelizumab-based chemoimmunotherapy demonstrates comparable efficacy and safety to camrelizumab-based regimens, potentially representing a viable neoadjuvant option for locally advanced ESCC. |
| format | Article |
| id | doaj-art-fa7d67fbfa7544ea9a384c48b49b5da8 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-fa7d67fbfa7544ea9a384c48b49b5da82025-08-21T04:10:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.15447391544739Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective studyQi Zhao0Yusen Yuan1Tongxin Xu2Ningning Yan3Fei Li4Juntao Lu5Ming He6Zhaoyang Yan7Department of Thoracic Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of CT&MRI, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaLaboratory of Pathology, Hebei Cancer Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaBackgroundWhile neoadjuvant chemoimmunotherapy shows promise for locally advanced esophageal squamous cell carcinoma (ESCC), optimal regimen selection remains challenging. This study compares perioperative outcomes between camrelizumab- and tislelizumab-based neoadjuvant chemoimmunotherapy in ESCC.MethodsWe conducted a retrospective analysis of 209 clinical stage II-IVA ESCC patients treated at Hebei Medical University Fourth Hospital (October 2020-December 2023) who underwent neoadjuvant chemoimmunotherapy (camrelizumab, n=119; tislelizumab, n=90) followed by esophagectomy.ResultsComparable pathological responses were observed between groups: pathological complete response (31.1% vs 30.3%, P=1.00), major pathological response (44.4% vs 42.9%, P=0.89), and pathological downstaging (67.8% vs 73.9%, P=0.36). Perioperative complication rates, including hematologic toxicities, immune-related adverse events, and surgical complications, were similar (all P>0.05). The tislelizumab group demonstrated significantly lower unplanned ICU transfer rates (P=0.04), while operative parameters (duration, blood loss, R0 resection) showed no differences.ConclusionTislelizumab-based chemoimmunotherapy demonstrates comparable efficacy and safety to camrelizumab-based regimens, potentially representing a viable neoadjuvant option for locally advanced ESCC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544739/fullesophageal squamous cell carcinomaneoadjuvant therapytislelizumabcamrelizumabimmunotherapyesophagectomy |
| spellingShingle | Qi Zhao Yusen Yuan Tongxin Xu Ningning Yan Fei Li Juntao Lu Ming He Zhaoyang Yan Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study Frontiers in Immunology esophageal squamous cell carcinoma neoadjuvant therapy tislelizumab camrelizumab immunotherapy esophagectomy |
| title | Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study |
| title_full | Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study |
| title_fullStr | Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study |
| title_full_unstemmed | Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study |
| title_short | Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study |
| title_sort | perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer a real world retrospective study |
| topic | esophageal squamous cell carcinoma neoadjuvant therapy tislelizumab camrelizumab immunotherapy esophagectomy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544739/full |
| work_keys_str_mv | AT qizhao perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy AT yusenyuan perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy AT tongxinxu perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy AT ningningyan perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy AT feili perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy AT juntaolu perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy AT minghe perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy AT zhaoyangyan perioperativeoutcomesofneoadjuvantchemotherapypluscamrelizumabversusneoadjuvantchemotherapyplustislelizumabforlocallyadvancedesophagealsquamouscellcancerarealworldretrospectivestudy |